ABEO stock news · Abeona Therapeutics Inc.
Get alerts for ABEO
Follow Abeona Therapeutics Inc. (ABEO) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ABEOAbeona Therapeutics shared its financial results for the quarter ending September 30, 2026.
NeutralAbeona said it issued a release about quarterly results and shared an investor presentation, but this text gives no results figures. It does not show a change in the company's outlook.
Abeona Therapeutics has signed a deal to buy assets for APT-1011, a treatment for eosinophilic esophagitis.
NeutralAbeona acquired an EoE drug candidate for $20 million in stock, or 4,494,383 shares, plus possible future payments. The new opportunity and its costs leave the company's outlook mixed.
Abeona Therapeutics Inc. shares new info for investors ahead of a big conference on September 15, 2026.
NeutralAbeona furnished an investor presentation on Form 8-K for a Sept 15 conference; the filing contains no new financial or clinical information, so it does not change Abeona's outlook.
Transcript of Abeona Therapeutics' Q2 2026 Earnings Conference Call
NeutralAbeona Therapeutics' Q2 2026 earnings call revealed a strong revenue increase for ZEVA Skin and operational advancements, including the achievement of NTAP status, which is expected to positively influence the company's market position and investor confidence.